Asia stocks edge higher as tech meanders on Nvidia; Hong Kong hit by soft earnings
HealthEquity, Inc. (NASDAQ:HQY), a $6.66 billion market cap company, saw its Executive Vice President and Chief Commercial Officer Michael Fiore recently sell a significant portion of his holdings. According to a filing with the Securities and Exchange Commission, Fiore sold 8,881 shares of common stock on April 4, 2025, at an average price of $78.2621 per share, amounting to a total transaction value of approximately $695,045. The transaction comes as the stock has experienced a notable 7.7% decline over the past week.
Following this sale, Fiore retains ownership of 56,655 shares in HealthEquity. The transaction was executed under a Rule 10b5-1 trading plan, which Fiore adopted on December 18, 2024. Rule 10b5-1 plans allow insiders to set up a predetermined schedule for selling stocks, helping to avoid potential accusations of insider trading. According to InvestingPro data, analysts maintain a bullish outlook on the stock, with price targets ranging from $94 to $130.
HealthEquity, headquartered in Draper, Utah, provides a range of services in the business services sector, focusing on health savings accounts and other consumer-directed benefits. The company maintains strong financial health with a current ratio of 3.06 and has demonstrated robust revenue growth of 20% over the last twelve months. InvestingPro analysis reveals 12 additional key insights about HealthEquity's performance and prospects, available through the comprehensive Pro Research Report.
In other recent news, HealthEquity, Inc. reported a revenue increase of 19% year-over-year for the fourth quarter, reaching $311.8 million, which surpassed analyst expectations. However, the company's earnings per share (EPS) of $0.69 fell short of the projected $0.72. The company's adjusted EBITDA for the quarter was $107.8 million, a 9% increase from the previous year, but still below expectations. HealthEquity's financial performance was impacted by $17 million in additional service costs related to fraud mitigation. Raymond (NSE:RYMD) James upgraded HealthEquity's stock rating from Outperform to Strong Buy, reflecting confidence in the company's ability to manage fraud-related challenges, despite lowering the price target to $115. KeyBanc also adjusted its price target to $110 while maintaining an Overweight rating, citing optimism in HealthEquity's revenue growth potential. BTIG reaffirmed a Buy rating with a $130 price target, highlighting the company's strong revenue performance and future growth prospects. JMP Securities revised its price target to $110, maintaining a Market Outperform rating, following the company's earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.